ICM
MANH icon

Invenomic Capital Management’s Manhattan Associates MANH Stock Holding History

Invenomic Capital Management’s Portfolio MANH Stock Details MANH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,679
Closed -$6.75M – 138
2026
Q1 		$6.75M Buy
+50,679
New +$7.59M 0.31% 85

Other funds holding MANH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invenomic Capital Management's MANH Position: Q2 2026 in Review

Invenomic Capital Management sold out of Manhattan Associates (MANH) in Q2 2026, closing a stake of 50,679 shares — an estimated $6.75M sold.

Invenomic Capital Management first reported a position in MANH in Q1 2026 and held it in 1 quarter. The position peaked at $6.75M in Q1 2026. 504 funds tracked by Wall St. Rank hold MANH as of Q2 2026.

  • Invenomic Capital Management reported no remaining Manhattan Associates position as of Q2 2026 after selling out during the quarter.
  • Invenomic Capital Management sold 50,679 Manhattan Associates shares in Q2 2026, an estimated $6.75M.
  • Invenomic Capital Management first reported a position in Manhattan Associates in Q1 2026 and held it in 1 quarter.
  • Invenomic Capital Management's Manhattan Associates position peaked at $6.75M in Q1 2026.
  • 504 funds tracked by Wall St. Rank held Manhattan Associates as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.